UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000001487 |
|---|---|
| Receipt number | R000001805 |
| Scientific Title | A phase II study of gemcitabine in pancreatic endocrine tumor |
| Date of disclosure of the study information | 2008/11/07 |
| Last modified on | 2011/11/07 10:02:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phase II study of gemcitabine in pancreatic endocrine tumor
Acronym
A phase II study of gemcitabine in pancreatic endocrine tumor
Scientific Title
A phase II study of gemcitabine in pancreatic endocrine tumor
Scientific Title:Acronym
A phase II study of gemcitabine in pancreatic endocrine tumor
Region
| Japan |
Condition
Condition
pancreatic endocrine tumor
Classification by specialty
| Medicine in general | Hepato-biliary-pancreatic medicine | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
This study evaluated the efficacy and toxicity of gemcitabine in patients with pancreatic endcrine tumors.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
response rate
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
gemcitabine
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Histologically confirmed pancreatic endocrine tumors
2) metastatic lesion(s)
3) inoperable case
4) Measurable lesion(s)
5) Age of more than 20 years
6) ECOG performance status (PS) of 0 to 2
7) no prior chemotherapy for pancreatic endocrine carcinoma
8) Interval of at least 4 weeks between last treatment and start of present chemotherapy regimen
9) Adequate organ function
a. WBC : 3,000-12,000/mm3
b. neutrophils : 1,500/mm3
c. platelets : 100,000/mm3
d. Hb : 9.0 g/dL
e. T-Bil : 2.0 mg/dL
f. GOT, GPT : 5*wnl
g. Cr : 1.5 mg/dL
10) Written informed consent
Key exclusion criteria
1) Intestinal pneumonia or lung fibrosis
2) Massive pleural or abdominal effusion
3) Symptomatic brain metastasis
4) History of other active malignancy
5) Severe infection
6) Severe complication
7) Pregnancy or the desire to preserve fecundity
8) uncontrollable endocrine symptom
9) Inadequate physical condition, as diagnosed by primary physician
Target sample size
18
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Chigusa Morizane |
Organization
National Cancer Center Hospital
Division name
Hepatobiliary and Pancreatic Oncology Division
Zip code
Address
5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
TEL
03-3542-2511
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Chigusa Morizane |
Organization
National Cancer Center Hospital
Division name
Hepatobiliary and Pancreatic Oncology Division
Zip code
Address
5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
TEL
Homepage URL
Sponsor or person
Institute
National Cancer Center Hospital
Institute
Department
Personal name
Funding Source
Organization
Ministry of Health, Labor and Welfare
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 11 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2004 | Year | 11 | Month | 25 | Day |
Date of IRB
Anticipated trial start date
| 2004 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2008 | Year | 11 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2008 | Year | 11 | Month | 07 | Day |
Last modified on
| 2011 | Year | 11 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001805
